Vertex Innovation Awards
The Vertex Innovation Awards fund innovative clinical research by Vertex Pharmaceuticals to advance cystic fibrosis care, with a focus on CFTR modulators and patient outcomes.
Funder: Vertex Pharmaceuticals
Due Dates (Anticipated): October 2026 (Vertex Innovation Awards full application deadline, projected)
Funding Amounts: Up to $750,000 USD per project; up to four awards granted annually; funding typically covers multi-year clinical research.
Summary: Supports innovative, collaborative clinical research projects to advance care for people with cystic fibrosis.
Key Information: This is a forecasted opportunity—dates and program details are projected, not final.
Description
The Vertex Innovation Awards (VIA) are annual, competitive grants provided by Vertex Pharmaceuticals to support innovative and collaborative clinical research projects aimed at improving care for individuals with cystic fibrosis (CF). The program is designed for established clinical researchers with a demonstrated interest in CF, seeking to fund impactful projects that advance scientific understanding and patient outcomes. Applications are evaluated by an independent panel of external experts to ensure a rigorous and unbiased selection process. VIA grants are intended to foster high-impact discoveries and support the ongoing advancement of cystic fibrosis research.
